Dachaigh › Aillse a' bhroilleach › California › Los Angeles
Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Los Angeles, CA
Tha 73 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann agus timcheall air Los Angeles (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
A’ fastadhÌre 1/2
- Research Site, Los Angeles
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A’ fastadhÌre 3
- Cedars-Sinai Medical Center, Los Angeles
A Study of PHST001 in Advanced Solid Tumors
A’ fastadhÌre 1
- USC Norris Comprehensive Cancer Center, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A’ fastadhÌre 3
- Los Angeles Cancer Network Good Samaritan, Los Angeles
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
A’ fastadhÌre 1/2
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A’ fastadhÌre 2
- LA Cancer Network, Los Angeles
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A’ fastadhÌre 1
- University of California Los Angeles, Los Angeles
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
A’ fastadhÌre 1/2
- Ellison Medical Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- University of California Los Angeles, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A’ fastadhÌre 1
- Research Site, Los Angeles
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A’ fastadhÌre 3
- Los Angeles Hematology Oncology Medical Group ( Site 0026), Los Angeles
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
A’ fastadhÌre 2
- Los Angeles Cancer Network, Los Angeles
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A’ fastadhÌre 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A’ fastadhÌre 2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
A’ fastadhFàilte do shaor-thoilich fhallain
- University of California Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
A’ fastadhÌre 3
- Ellison Medical Institute, Los Angeles
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A’ fastadhÌre 3
- Cedar Sinai - Samuel Oschin Cancer Center, Los Angeles
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- University of California, Los Angeles (Specimen Analysis only), Los Angeles
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A’ fastadhÌre 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
A’ fastadhÌre 1/2
- UCLA Health 200 Medical Plaza, Los Angeles
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A’ fastadhÌre 1
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A’ fastadhÌre 1
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
A’ fastadhÌre 1/2
- California Research Institute, Los Angeles
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
A’ fastadhÌre 1/2
- START Los Angeles, Los Angeles
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
A’ fastadhÌre 2
- Los Angeles Cancer Network, Los Angeles
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A’ fastadhÌre 3
- Ellison Medical Institute, Los Angeles
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A’ fastadhÌre 3
- Los Angeles Cancer Network, Los Angeles
- Cedars-Sinai Cancer at Cedars-Sinai Medical Facility, Los Angeles
- Los Angeles Cancer Network_Century City, Los Angeles
- agus 3 a bharrachd
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- University of Southern California, Los Angeles
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
A’ fastadhÌre 3
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- agus 2 a bharrachd
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
A’ fastadhÌre 1
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
A’ fastadhÌre 1/2
- University of California LA, Los Angeles
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- START Los Angeles, Los Angeles
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
A’ fastadhÌre 2
- Univ. of California Los Angeles, Los Angeles
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
A’ fastadhÌre 1
- University California, Los Angeles, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- The Angeles Clinic and Research Institute, Los Angeles
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
A’ fastadhÌre 2
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A’ fastadhÌre 2/3
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
A’ fastadhÌre 1 tràth
- Cedars-Sinai Medical Center, Los Angeles
E-Mindfulness Approaches for Living After Breast Cancer
A’ fastadhÌre 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- agus 1 a bharrachd
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- University of California Los Angeles Medical Center, Los Angeles
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
A’ fastadhÌre 1
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
A’ fastadhÌre 1
- University of California LA, Los Angeles
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
A’ fastadhÌre 1
- START Los Angeles, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Ellison Clinic at Saint John's, Los Angeles
Brain Health in Breast Cancer Survivors
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- University of California at Los Angeles, Los Angeles
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
A’ fastadhÌre 1/2
- START Los Angeles, Los Angeles
EXoPERT EMERALD Clinical Study
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- City of Hope Duarte Cancer Center, Los Angeles
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
A’ fastadhÌre 2
- GSK Investigational Site, Los Angeles
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A’ fastadhÌre 3
- UCLA Hematology Oncology Santa Monica, Los Angeles
Core Biopsies for Establishing a Breast Tumor Tissue Repository
A’ fastadhSgrùdadh amharc
- USC Norris Comprehensive Cancer Center, Los Angeles
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A’ fastadhÌre 2
- University of Southern California, Los Angeles
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
A’ fastadhÌre 3
- Los Angeles Cancer Network - Good Samaritan, Los Angeles
- Los Angeles Hematology Oncology Medical Group, Los Angeles
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
A’ fastadh
- University of California Los Angeles, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
A’ fastadh
- Oncology Institute for Hope and Innovation, Los Angeles
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A’ fastadhÌre 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- agus 1 a bharrachd
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
A’ fastadhÌre 2
- Cedars-Sinai Medical Center, Los Angeles
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
A’ fastadh
- Beckman Research Institute of the City of Hope, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
A’ fastadhFàilte do shaor-thoilich fhallain
- USC / Norris Comprehensive Cancer Center, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
A’ fastadhÌre 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
A’ fastadhSgrùdadh amharc
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
A’ fastadhÌre 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
A’ fastadhÌre 1
- Los Angeles County-USC Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer
A’ fastadh
- UCLA, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
A’ fastadhÌre 1/2
- University of Southern California, Los Angeles
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
A’ fastadhÌre 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
A’ fastadhFàilte do shaor-thoilich fhallain
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
A’ fastadhÌre 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Cedars Sinai Medical Center, Los Angeles
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
A’ fastadhÌre 2
- Valkyrie Clinical Trials, Los Angeles
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
A’ fastadhÌre 1/2
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- MiraKind, Los Angeles
Sgrùdaidhean Aillse a' bhroilleach ann am bailtean eile
- New York City, NY136 sgrùdaidhean
- Houston, TX126 sgrùdaidhean
- Boston, MA112 sgrùdaidhean
- Nashville, TN81 sgrùdaidhean
- Edison, NJ68 sgrùdaidhean
- St. Louis, MO64 sgrùdaidhean
- Queens, NY64 sgrùdaidhean
- Durham, NC64 sgrùdaidhean
- Chicago, IL59 sgrùdaidhean
- Philadelphia, PA56 sgrùdaidhean
- Dallas, TX55 sgrùdaidhean
- Arlington, VA47 sgrùdaidhean
Sgrùdaidhean eile ann an Los Angeles
- Aillse Sgamhain Neo-chealla-beag87 sgrùdaidhean
- Aillse (gach seòrsa)74 sgrùdaidhean
- Aillse Prostata61 sgrùdaidhean
- Aillse colorectal59 sgrùdaidhean
- Ailse metastatach57 sgrùdaidhean
- Cancer Ovarian50 sgrùdaidhean
- Ailseachadh nan Sgamhan45 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil42 sgrùdaidhean
- Cancer Pancreatic35 sgrùdaidhean
- Ailse Endometrial34 sgrùdaidhean
- Melanoma34 sgrùdaidhean
- Cancer briste triple-negative27 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.